Quillivant XR and Breastfeeding
Quillivant XR (methylphenidate ER oral solution) does pass through human breast milk. Although it has been shown to pass through breast milk in low amounts, the potential long-term effects of using Quillivant XR while breastfeeding have not been studied. Do not use this medication while nursing without first talking to your healthcare provider about the potential risks.
Quillivant XR™ (methylphenidate ER oral suspension) passes through breast milk in humans. The manufacturer of the drug recommends that women not breastfeed while taking Quillivant XR. Therefore, if you are breastfeeding or plan to start, talk with your healthcare provider before taking this medication.
Quillivant XR has been shown to pass through human breast milk. Based on available information, the amount passed to a nursing infant is expected to be low. In addition, no problems have been reported in nursing infants exposed to Quillivant XR through breast milk.
However, it is important to point out that the information on this issue comes from a limited number of reports. While the drug has not been reported to cause immediate side effects, the possible long-term effects of Quillivant XR on a nursing infant have not been studied. Therefore, it is not entirely known whether Quillivant XR could interfere with a nursing infant's brain development and lead to long-term neurological problems.
In addition, there is very little information available on the possible effects of the drug on very young nursing infants. Infants who are less than one month of age may have the greatest risk for problems if exposed to Quillivant XR through breast milk.
If your healthcare provider recommends Quillivant XR while breastfeeding, be sure to watch for any signs of problems in your infant. Such problems may include decreased appetite, irritability, and insomnia. Let your child's healthcare provider know right away if you notice these symptoms, or if anything else just doesn't seem right.